Psychedelic therapy is a structured form of mental health treatment that combines a controlled dose of a psychedelic substance with professional psychological support. Unlike taking a medication daily, it typically involves just one to three dosing sessions, each lasting six to eight hours, embedded within a broader course of talk therapy. The approach is being studied primarily for treatment-resistant depression, PTSD, and anxiety, with early clinical results that exceed what most existing treatments deliver.
How the Three Phases Work
Psychedelic therapy follows a consistent three-phase structure: preparation, the dosing session itself, and integration afterward. Each phase is considered essential to the outcome, and skipping or rushing any of them appears to reduce effectiveness.
During preparation, you meet with a trained therapist for several hours to discuss your history, what you’re hoping to address, and what your symptoms look like. The therapist walks you through what the psychedelic experience may feel like, gives you tools for managing difficult emotions or physical sensations that can arise, and establishes clear rules and boundaries to keep you safe. This phase builds trust between you and your therapist, which matters because the dosing session can bring up intense and unexpected psychological material.
The dosing session is where the substance is administered in a supervised clinical setting. For psilocybin, sessions average about 7.5 hours. For MDMA, they run 6 to 8 hours. You’re typically in a comfortable room, often lying down with eyeshades and music, while one or two therapists remain present. Their role is largely non-directive: they don’t guide you toward specific topics or interpretations. Instead, they provide a calm, supportive presence and step in only if you become distressed or need grounding.
Integration comes after the drug’s effects have worn off. This is where you and your therapist work through whatever surfaced during the experience, whether that’s memories, emotions, new perspectives on old patterns, or something harder to articulate. Psilocybin protocols typically include around six integration sessions. The early stage of integration usually spans about five one-hour sessions covering standard therapeutic practices: processing the experience, identifying insights, and connecting them to your daily life.
What Happens in Your Brain
Psychedelics produce their therapeutic effects through at least two pathways that researchers are still working to untangle from each other.
The first involves a brain network called the Default Mode Network, a set of interconnected regions that are most active when you’re at rest, daydreaming, or thinking about yourself. This network plays a central role in your sense of identity, your internal narratives, and habitual thought patterns. Altered connectivity in this network has been linked to depression, anxiety, PTSD, OCD, and several other psychiatric conditions. Psychedelics consistently disrupt the normal communication within this network while simultaneously increasing connections between brain regions that don’t usually talk to each other. The result is a temporary state of heightened flexibility, where rigid patterns of thinking loosen and the brain enters a wider range of dynamic states. Researchers describe this as increased “brain entropy,” meaning greater unpredictability and flexibility in brain activity.
The second pathway involves neuroplasticity, the brain’s ability to physically rewire itself. Psychedelics trigger the growth of new neural connections through signaling molecules that promote neuron survival and branching. These structural changes may help rewire the pathological circuits underlying conditions like depression and addiction, possibly by reducing neuronal inflammation. It remains unclear how much of the therapeutic benefit comes from this cellular-level rewiring versus the network-level shifts in connectivity, or how deeply the two processes depend on each other.
Psychedelics also frequently produce what people describe as deeply meaningful or even mystical experiences. These subjective experiences correlate with better treatment outcomes, suggesting that the psychological content of the session matters alongside the biological changes.
Clinical Results So Far
The strongest evidence exists for two conditions: PTSD treated with MDMA and depression treated with psilocybin.
Across two Phase 3 clinical trials for MDMA-assisted therapy, 67% to 71% of participants no longer met the diagnostic criteria for PTSD about four weeks after their final dosing session. In the placebo groups, where participants received therapy with an inactive substance, 32% to 48% lost their diagnosis. That gap is significant. PTSD is notoriously difficult to treat, and many participants in these trials had not responded to previous therapies.
For psilocybin and depression, a systematic review and meta-analysis found pooled remission rates of 45% for psilocybin versus 22% for comparison groups. Response rates, meaning meaningful improvement even if full remission wasn’t achieved, also strongly favored psilocybin. Notably, dropout rates were equivalent between groups, suggesting that side effects or the intensity of the experience didn’t drive people away from treatment at higher rates.
Which Substances Are Used
Three substances dominate the current landscape, each with a different profile.
- Psilocybin is the active compound in certain mushrooms. It’s being studied most extensively for treatment-resistant depression and major depressive disorder. Protocols typically involve one or two dosing sessions plus about six therapy sessions before and after. Multiple companies have received FDA breakthrough therapy designations for psilocybin treatments, including one for treatment-resistant depression and another for major depressive disorder.
- MDMA produces effects that are distinct from classical psychedelics: increased feelings of trust, emotional openness, and reduced fear responses. This makes it particularly suited for trauma processing. The most developed protocol includes twelve 90-minute therapy sessions plus three separate medicine sessions. However, in 2024, the FDA rejected the application for MDMA-assisted therapy for PTSD, a decision that drew criticism from researchers and advocacy groups.
- Ketamine is the only substance currently available through legal medical channels in the United States. It can be prescribed off-label by physicians, and hundreds of ketamine clinics now operate across the country. A nasal spray formulation has full FDA approval for treatment-resistant depression. Ketamine works through different brain receptors than classical psychedelics, and sessions are shorter, though the therapeutic framework of preparation and integration still applies.
Who Should Not Receive It
Psychedelic therapy carries specific risks for certain groups, and clinical trials consistently exclude people with these conditions. If you have a personal or family history of psychotic disorders like schizophrenia, schizoaffective disorder, or bipolar I disorder, psychedelics are contraindicated. The substances can trigger prolonged psychotic episodes in vulnerable individuals. This also applies to people who experience psychotic symptoms in the context of depression.
Severe cardiovascular conditions are another exclusion. Psychedelics raise heart rate and blood pressure, making them unsafe for people with uncontrolled blood pressure, heart failure, coronary artery disease, or a history of heart attack or stroke. Pregnancy and epilepsy or other seizure disorders are also contraindications. Anyone who has previously experienced prolonged psychosis or suicidal ideation following psychedelic use should not repeat the experience.
What Integration Actually Looks Like
Integration is often described as the most important and most overlooked part of psychedelic therapy. A dosing session can produce powerful insights, emotional breakthroughs, or shifts in perspective, but without a structured process to make sense of them, those experiences may fade without translating into lasting change.
In the days following a session, integration work often begins with grounding exercises: paying attention to physical sensations, doing body scans, stretching, mindful walking, or spending time in nature. These activities help reconnect you with your body and your surroundings after what can be a disorienting experience. Therapists frequently recommend self-expression activities like writing, painting, singing, or dancing as ways to process material that doesn’t fit neatly into words.
Beyond these immediate practices, integration involves exploring your own biography for skills, values, meaningful memories, and sources of strength. The goal is to take whatever emerged during the psychedelic experience and weave it into how you actually live. This might mean recognizing a pattern you want to change, reconnecting with something you’d forgotten about yourself, or simply sitting with a new emotional understanding of an old wound. The early integration phase typically lasts about five sessions, though many people continue the process informally for months.
Current Legal and Regulatory Status
The legal landscape for psychedelic therapy is uneven and shifting. Ketamine remains the most accessible option, available through licensed clinics and prescribers across the United States. Oregon and Colorado have created state-regulated frameworks allowing supervised psilocybin use outside of clinical trials, though the infrastructure is still developing and sessions can be expensive.
At the federal level, the FDA has granted breakthrough therapy designations to four commercial entities studying classical psychedelics, a status meant to speed development of drugs that show substantial improvement over existing treatments. Despite this, the FDA’s 2024 rejection of MDMA for PTSD signaled that the path from promising trial data to approved medicine is not straightforward. The agency cited concerns about trial methodology, and the decision was widely seen as a setback for the field. Psilocybin-based treatments continue moving through the FDA pipeline, but no classical psychedelic has received full federal approval for therapeutic use.